Literature DB >> 21690428

Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease.

Robert Barrons1, Angela Pegram, Alaina Borries.   

Abstract

PURPOSE: Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.
SUMMARY: Substantial deficiencies in inhaler device technique and medication adherence are evident in patients with COPD, leading to suboptimal health outcomes. As the prevalence of COPD rises with age, elderly patients pose special challenges with regard to inhaler device selection. In elderly patients with sufficient cognitive function, manual dexterity, and hand strength, the most influential factors in inhaler selection are cost reimbursement, device availability, device convenience, and patient preference. Cost reimbursement may be a deciding factor in device selection, as nearly all elderly patients are Medicare beneficiaries. Nebulizers provide a cost-effective alternative to pressurized metered-dose inhaler (pMDI) and dry powder inhaler (DPI) devices. DPI device availability is limited to "controller" medications, while pMDI devices and nebulizers provide complete symptomatic coverage. Multiple-dose DPIs offer the convenience of rapid medication administration, ease of handling, and integral dose counters. Given the availability and expenses of medication devices, ambulatory patients may prefer combining the convenience of a hand-held inhaler (i.e., pMDI) as a rescue medication during the active hours of midday with the cost savings of a nebulized controller medication in the morning and at night.
CONCLUSION: In elderly patients with sufficient cognitive function, manual dexterity, and hand strength, the most important factors in inhaler device selection are cost reimbursement issues, device availability, device convenience, and patient preference. Pharmacist knowledge of appropriate inhaler technique, competent patient education and demonstration, and follow-up assessment are instrumental in optimizing device competency and medication adherence.

Entities:  

Mesh:

Year:  2011        PMID: 21690428     DOI: 10.2146/ajhp100452

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  41 in total

Review 1.  Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting.

Authors:  Roy A Pleasants; Peter A Radlowski; H Edward Davidson
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

2.  Inhaler assessment in COPD patients: A primer for pharmacists.

Authors:  Shelby Dougall; Jennifer Bolt; William Semchuk; Tanya Winkel
Journal:  Can Pharm J (Ott)       Date:  2016-07-27

3.  Evaluation of Bronchodilator Use During Chronic Obstructive Pulmonary Disease Exacerbation Inpatient Admissions.

Authors:  Sarah E Petite; Julie A Murphy
Journal:  Hosp Pharm       Date:  2018-04-10

4.  Indacaterol (arcapta neohaler) for chronic obstructive pulmonary disease.

Authors:  Rachel M Slaton; Danielle L Cruthirds
Journal:  P T       Date:  2012-02

Review 5.  Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations.

Authors:  Nicola Scichilone; Fulvio Braido; Federico Lavorini; Mark L Levy; Omar S Usmani
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 6.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

Review 7.  Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.

Authors:  Federico Lavorini; Claudia Mannini; Elisa Chellini; Giovanni A Fontana
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

Review 8.  Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies.

Authors:  Soojin Cho-Reyes; Bartolome R Celli; Carole Dembek; Karen Yeh; Maryam Navaie
Journal:  Chronic Obstr Pulm Dis       Date:  2019-07-24

9.  Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.

Authors:  Maryam Navaie; Bartolome R Celli; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

10.  Patient preference for a maintenance inhaler in chronic obstructive pulmonary disease: a comparison of Breezhaler and Respimat.

Authors:  Philip O'Hagan; Juergen Dederichs; Boomi Viswanad; Matthias Gasser; Susann Walda
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.